Monoclonal antibody
Treatment of SARS-CoV-2 infection
Target
SARS-CoV-2 spike glycoprotein [KO:K24152]
Pathway
ko03230
Viral genome structure
ko05171
Coronavirus disease - COVID-19
Brite
Drug groups [BR:br08330]
Antiviral
DG03174 Anti-SARS-CoV-2 agent
D12174 Bebtelovimab
Drug classes [BR:br08332]
Antiviral
DG03174 Anti-SARS-CoV-2 agent
D12174 Bebtelovimab
Antimicrobials [BR:br08307]
Antivirals
Entry, fusion or uncoating inhibitor
Coronavirus spike protein
D12174 Bebtelovimab (USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D12174
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D12174